QIAGEN N.V. develops Sample to Insight technologies for extracting, purifying, amplifying and interpreting DNA, RNA and proteins. Its recurring news covers life sciences and molecular diagnostics applications, including sample technologies, assay technologies, bioinformatics and laboratory automation used in clinical healthcare, pharmaceutical research, academia, forensics and other research settings.
Company updates frequently address product and regulatory developments across QuantiFERON tuberculosis testing, QIAstat-Dx syndromic testing panels, QIAcuity digital PCR, QIAGEN Digital Insights and automated sample-preparation systems such as QIAsymphony and QIAstat-Dx Rise. Financial news also tracks sales trends across consumables, instruments and services, profitability measures, capital-return actions, acquisitions, and changes affecting portfolio growth areas.
QIAGEN N.V. (NYSE: QGEN) reported strong preliminary results for Q3 2020, with net sales rising 26% year-over-year to $481.3 million, surpassing prior growth forecasts. This growth is attributed to heightened demand for COVID-19 testing solutions, along with improved trends in non-COVID product sales. Adjusted EPS reached approximately $0.58, marking a 61% increase from $0.36 in Q3 2019. QIAGEN anticipates minimal currency impact on its results. Full Q3 results will be published on November 4, 2020, with a conference call scheduled for November 5.
QIAGEN (NYSE: QGEN) has announced a new approach to viral RNA epidemiology with its QIAprep Viral RNA UM Kit. This innovative kit simplifies PCR analysis for SARS-CoV-2 and other RNA viruses, allowing sample preparation in just two minutes. The streamlined process delivers results in under one hour, significantly faster than traditional methods that take about three hours. The kit can manage up to 2,600 samples in an eight-hour shift and minimizes plastic use while reducing reagent and labor costs. Initial studies show detection levels comparable to standard protocols.